Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Study:

A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Rationale:

n/a

Purpose:

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Non-small Cell Lung Cancer(NSCLC) Drug: AT13387
Drug: Crizotinib
Phase 1/Phase 2

Verified by Astex Pharmaceuticals January, 2014

Sponsored by: Astex Pharmaceuticals
Information provided by: Astex Pharmaceuticals
ClinicalTrials.gov identifier: NCT01712217

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Jean-Charles Soria, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site